Navigation Links
Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
Date:6/19/2012

NEW YORK, June 19, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that its upcoming Analyst Day will be webcast live on Thursday, June 21, 2012 at 4:30 pm ET. Scheduled speakers include:

Julia Lewis, M.D., will provide her perspective on the Zerenex (ferric citrate) Phase 3 clinical program and the potential Zerenex product profile.
-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine.

Geoffrey Block, M.D., will discuss the potential for Zerenex in pre-dialysis.
-- Director of Research, Denver Nephrology and Associate Clinical Professor in Medicine, University of Colorado Health Sciences Center.

David Goldfarb, M.D., will discuss the potential importance of citrate.
-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.

To access the live audio webcast, please visit the Company's Investor Relations section of their website (http://investors.keryx.com). An archived version of the webcast will become available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.  

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
4. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
5. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
6. OncoSec Announces Issuance of New Patent for Method of Use
7. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
8. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
9. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
10. UK supplier of graphenes announces exclusive sales agency agreement with leading USA distributor
11. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate ... its decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. ... against DPCL and one of its Dishman Group’s 100% wholly owned New Jersey-based ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The biosimilars market is expected to reach USD ... a CAGR of 26.3%. The global biosimilars market ... Factors such as rising incidence of various diseases, increasing demand for ...
(Date:1/13/2017)... ... 13, 2017 , ... FireflySci has been busy rolling out ... diverse customer base. The latest entry in this field is a series of ... Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, 10x2 and 10x4 ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... Research Future published a half cooked research report on Mobile Biometric ... Market is expected to grow over the CAGR of ~35% during ... ... Mobile Biometric Security and Service Market is increasing at a ... security from unwanted cyber threats. The increasing use of mobile device ...
(Date:12/7/2016)... 2016 BioCatch , the global leader in ... portfolio, which grew to over 40 granted and pending patents. ... , , The ... " System, Device, and Method Estimating Force Applied to a ... to forego costly hardware components needed to estimate the force and pressure ...
Breaking Biology News(10 mins):